Roivant Sciences Ltd.
—Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
-6.6%
Net income / ending assets
-5.3%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROIV stock price vs HRB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HRB's multiple
Needs HRB P/B.
Implied fair value · at ROIV's multiple
Needs ROIV P/B.
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
15 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
-6.6%
Net income / ending assets
-5.3%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity (USD)
-$962.04M
Price / tangible book
—
Price / book
—
Net income / ending equity
624.4%
Net income / ending assets
22.5%
Efficiency ratio
—
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
H&R Block, Inc. · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
INTUIT INC.
ROIV vs INTU
AUTOMATIC DATA PROCESSING INC
ROIV vs ADP
PAYCHEX INC
ROIV vs PAYX
Block, Inc.
ROIV vs SQ
Blucora, Inc.
ROIV vs BCOR
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ROIV can rapidly reverse its negative growth and margin profile into sustained profitability, then a small speculative position may be justified; otherwise, avoid or underweight ROIV because the current price is far above HRB-implied range and is not supported by the provided fundamentals.
ROIV’s current price of $35.13 sits inside its own historical band of $31.62 to $38.64, but it is far above HRB-implied range of $0.02 to $4.46. The gap is driven by ROIV’s extreme multiples versus HRB, including a 3,059.1x P/S and -65.1x P/E versus HRB’s 1.3x P/S and 9.1x P/E.
Supporting Metrics